摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基[1,3]噁唑并[4,5-b]吡啶 | 86467-39-2

中文名称
2-甲基[1,3]噁唑并[4,5-b]吡啶
中文别名
2-甲基噁唑并[4,5-B]吡啶
英文名称
2-methyloxazolo[4,5-b]pyridine
英文别名
2-methyloxazolo<4,5-b>pyridine;2-methyloxazole[4,5-b]pyridine;2-methyl-[1,3]oxazolo[4,5-b]pyridine
2-甲基[1,3]噁唑并[4,5-b]吡啶化学式
CAS
86467-39-2
化学式
C7H6N2O
mdl
MFCD05256196
分子量
134.137
InChiKey
CTXHOLCMGDAANM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    74 °C(Solv: ligroine (8032-32-4))
  • 沸点:
    214.3±13.0 °C(Predicted)
  • 密度:
    1.229±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:c48de670917dcfa3120f967711d9071a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Methyloxazolo[4,5-b]pyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyloxazolo[4,5-b]pyridine
CAS number: 86467-39-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6N2O
Molecular weight: 134.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-甲基[1,3]噁唑并[4,5-b]吡啶三甲基氯硅烷 作用下, 以 N,N-二甲基甲酰胺乙腈 为溶剂, 反应 4.0h, 生成 2-(2-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)vinyl)-4-methyloxazolo[4,5-b]pyridin-4-ium iodide
    参考文献:
    名称:
    基于恶唑并吡啶鎓的粘度敏感内质网荧光探针
    摘要:
    本文通过二亚甲基连接香豆素和恶唑并吡啶鎓合成了一系列粘度敏感荧光探针1a-e 。探针1a-e的粘度测试表明,随着体系粘度的增加(0.89-865 cP),探针的荧光强度显着增强,并且在 648 nm、650 nm 和分别为 650nm。此外,与探针1a-e共培养后,细胞仍具有较高的存活率12 小时 (94–98%)。同时,激光共聚焦实验表明,恶唑并吡啶中碳链长度的变化会影响探针在细胞中定位的亚细胞区域。当恶唑并吡啶中的碳链长度在n -C 7 H 15和n -C 12 H 23之间时,探针1b-d具有靶向细胞内质网的能力。此外,在连续激光共聚焦照射 35 分钟后,探针1b-d的荧光强度没有显着变化,表明它们具有优异的抗光漂白性能。
    DOI:
    10.1039/d1tb01106e
  • 作为产物:
    描述:
    3-乙酰氧基-1-乙酰基-2-乙酰亚氨基-1,2-二氢-吡啶 在 ammonium hydroxide 、 phosphorus pentoxide 作用下, 生成 2-甲基[1,3]噁唑并[4,5-b]吡啶
    参考文献:
    名称:
    Takahashi; Yoneda, Pharmaceutical Bulletin, 1957, vol. 5, p. 350,352
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 高光学稳定性细胞膜荧光标记物及其制备方 法与应用
    申请人:苏州大学
    公开号:CN111560026B
    公开(公告)日:2021-08-27
    本发明公开了高光学稳定性细胞膜荧光标记物及其制备方法与应用,将2‑甲基噁唑[4,5‑b]吡啶与卤代烷烃反应得到化合物4;化合物4与化合物5反应,得到高光学稳定性细胞膜荧光标记物,可以作为细胞膜荧光标记物;本发明首次公开了一类高光学稳定性的细胞膜荧光标记物,改善了细胞膜荧光标记物的生物活性,公开解决了现有细胞膜标记物光稳定性差的问题;而且本发明公开的高光学稳定性的细胞膜标记物,可以通过改变荧光团来调控标记物发射波长,使细胞膜标记物可以用于不同通道化合物的标记;另外本发明的高光学稳定性的细胞膜荧光标记物通过将细胞膜荧光标记物与β‑环糊精形成主客体包合物来增加细胞膜标记物的光学性能,这具有重大的科学意义和商业价值。
  • N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
    申请人:Rodgers James D.
    公开号:US20100298334A1
    公开(公告)日:2010-11-25
    The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及式I的N-(杂)芳基吡咯烷衍生物: 这些是JAK抑制剂,如选择性JAK1抑制剂,在治疗JAK相关疾病方面具有用处,例如炎症和自身免疫性疾病,以及癌症。
  • A series of novel cell membrane fluorescent probes based on oxazolopyridine unit
    作者:Ya-Nan Wang、Bing Xu、Li-Hua Qiu、Yu-Jie Xu、Ru Sun、Jian-Feng Ge
    DOI:10.1016/j.dyepig.2020.108883
    日期:2021.2
    the remaining absorption of the probes was 81–97%. The cytotoxicity test indicated that the survival rate of HeLa and L929 cells was 94–119% after co-cultured with probes 1a-d for 6 h. Laser confocal experiments further illustrated that the probes could quickly (<1 min) combine with the cell membrane. Among them, probe 1a worked in the green channel, while probes 1b, 1c and 1d employed in the red
    荧光细胞膜探针(1a-d)是由具有生物活性的恶唑啉[4,5- b ]吡啶单元设计的。探针分别通过恶唑并[4,5- b ]吡啶和苯并呋喃(1a),三苯基(1b),香豆素(1c),二乙氨基苯(1d)连接,并具有双键。1a-d的光学性质使用不同的溶剂进行测试,它们在不同的极性溶剂中具有明显的溶剂变色现象,较大的斯托克斯位移(63–204 nm),并且在大型多层囊泡(MLV)中具有明显的荧光增强作用。连续照射6小时后,探针的剩余吸收率为81–97%。细胞毒性试验表明,将HeLa和L929细胞与探针1a-d共培养6小时后,其存活率为94–119%。激光共聚焦实验进一步表明,探针可以快速(<1分钟)与细胞膜结合。其中,探针1a在绿色通道中工作,而探针1b,1c和1d在红色通道中工作。此外,探针1a和1b的保留时间发现细胞膜上的1c持续2至3 h。
  • meta-Selective C–H Borylation of Benzamides and Pyridines by an Iridium–Lewis Acid Bifunctional Catalyst
    作者:Lichen Yang、Nao Uemura、Yoshiaki Nakao
    DOI:10.1021/jacs.9b03138
    日期:2019.5.15
    We report herein the iridium-catalyzed meta-selective C-H borylation of benzamides by using a newly designed 2,2'-bipyridine (bpy) ligand bearing an alkylaluminum biphenoxide moiety. We also demonstrate the iridium-catalyzed C3-selective C-H borylation of pyridine with a 1,10-phenanthroline (Phen) ligand bearing an alkylborane moiety. It is proposed that the Lewis acid-base interaction between the
    我们在此报告了通过使用新设计的带有烷基铝联苯氧化物部分的 2,2'-联吡啶 (bpy) 配体,铱催化的苯甲酰胺的间位选择性 CH 硼酸化。我们还展示了吡啶与带有烷基硼烷部分的 1,10-菲咯啉 (Phen) 配体的铱催化的 C3 选择性 CH 硼酸化。提出路易斯酸部分与氨基羰基或 sp2 杂化氮原子之间的路易斯酸碱相互作用加速反应并控制位点选择性。
  • Mild and Efficient Synthesis of Benzoxazoles, Benzothiazoles, Benzimidazoles, and Oxazolo[4,5-b]pyridines Catalyzed by Bi(III) Salts Under Solvent-Free Conditions
    作者:Iraj Mohammadpoor-Baltork、Ahmad R. Khosropour、Seyedeh F. Hojati
    DOI:10.1007/s00706-007-0655-9
    日期:2007.7
    A series of benzoxazoles, benzothiazoles, benzimidazoles, and oxazolo[4,5- b ]pyridines was efficiently synthesized from the reactions of o -aminophenols, o -aminothiophenol, o -phenylenediamines, and 2-amino-3-hydroxypyridine with orthoesters in the presence of catalytic amounts of Bi(III) salts, such as Bi( TFA )3, Bi(O Tf )3, and BiOClO4 · x H2O under solvent-free conditions. The remarkable features
    一系列苯并恶唑,苯并噻唑,苯并咪唑,和恶唑并[4,5- b ]吡啶化合物是有效地从的反应合成 Ò 氨基苯酚, ö -aminothiophenol, ø 苯二胺类,和2-氨基-3-羟基吡啶与所述原酸酯存在催化量的Bi(III)盐,例如Bi( TFA )3,Bi(O Tf )3和BiOClO 4 · x H 2O在无溶剂条件下。该新方案的显着特征是高转化率,非常短的反应时间,在无溶剂条件下更干净的反应曲线,简单的操作步骤以及使用相对无毒的催化剂。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

甲基吡噁磷 甲基吡啶磷-d6 恶唑并[5,4-B]吡啶-2-胺二盐酸盐 恶唑并[5,4-B]吡啶-2-胺 恶唑并[5,4-B]吡啶-2(1H)-硫酮 恶唑并[4,5-B]吡啶-2(3H)硫酮 噁唑并[5,4-c]吡啶-2-胺 噁唑并[5,4-c]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶 噁唑并[4,5-c]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-羧酸乙酯 噁唑并[4,5-b]吡啶-2(3H)-酮,6-溴-3-(苯基甲基)- 噁唑并[4,5-b]吡啶-2(3H)-酮,6-乙酰基-3-[2-(2-吡啶基)乙基]- 噁唑并[4,5-b]吡啶-2(3H)-酮,3-(2-羰基丙基)- 噁唑并[4,5-b]吡啶,2-(1-甲基乙基)-(9CI) 噁唑并[4,5-b]吡啶 噁唑并[4,5-C]吡啶-2(3H)-硫酮 噁唑并[4,5-C]吡啶 [1,3]恶唑并[4,5-c]吡啶-6-羧酸 7-溴恶唑并[4,5-C]吡啶 7-溴-2-甲基-F唑并[4,5-C]吡啶 7-溴-2-乙基恶唑并[4,5-C]吡啶 6-溴恶唑并[5,4-B]吡啶-2-胺 6-溴恶唑并[5,4-B]吡啶 6-溴噁唑并[4,5-b]吡啶 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 6-溴-2-甲基噁唑并[5,4-b]吡啶 6-溴-2-甲基噁唑并[4,5-B]吡啶 6-溴-2-(三氟甲基)噁唑并[5,4-B]吡啶 6-溴-2-(三氟甲基)噁唑并[4,5-b]吡啶 6-氯恶唑并[4,5-b]吡啶-2(3H)-酮 5-甲基噁唑并[4,5-b]吡啶-2(3h)-酮 5-甲基-3H-恶唑并[4,5-B]吡啶-2-硫酮 5-溴-3H-恶唑并[4,5-b]吡啶-2-酮 3-[2-(4-氯苯基)乙基]-2-苯基亚氨基-1,3-噻唑烷-4-酮 3-(2-溴乙基)恶唑并[4,5-b]吡啶-2(3H)-酮 3-(2-吗啉-4-基乙基)[1,3]噁唑并[4,5-b]吡啶-2(3H)-酮 2-甲硫基唑并[4,5-B]吡啶 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 2-甲基噁唑并[5,4-c]吡啶 2-甲基噁唑并[5,4-b]吡啶 2-甲基吡啶并噁唑 2-甲基[1,3]噁唑并[4,5-b]吡啶 2-氯甲基噁唑并[4,5-b]吡啶 2-氯恶唑并[5,4-b]吡啶 2-氯恶唑并[5,4-C]吡啶盐酸盐 2-氯恶唑并[5,4-C]吡啶 2-氯噁唑并[4,5-B]吡啶